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Background/AimsTo compare blood tests of liver fibrosis specific for NAFLD: the
FibroMeter NAFLD and the NAFLD fibrosis score (NFSA) with a non-specific test,
APRI. Methods Two hundred and thirty-five NAFLD patients with liver Metavir
staging and blood markers from two independent centres were randomly assigned
to a test (n = 121) or a validation population (n = 114). Results The highest
accuracy – 91% – for significant fibrosis was obtained with the FibroMeter whose (i)
AUROC (0.943) was significantly higher than those of NFSA (0.884, p = 0.008) and
APRI (0.866, p < 10−3; p = 0.309 vs NFSA) in the whole population, and (ii)
misclassification rate (9%) was significantly lower than those of NFSA (14%, p =
0.04) and APRI (16%, p = 0.002) and did not vary according to centre (14 vs 7%, p =
0.07), unlike those of NFSA (25 vs 9%, p = 0.001) and APRI (29 vs 11%, p < 10−3).
By using thresholds of 90% predictive values, liver biopsy could have been avoided
in most patients: FibroMeter: 97.4% vs NFSA: 86.8% (p < 10−3) and APRI: 80.0% (p
< 10−3). A new classification provided three reliable diagnosis intervals: F0/1,
F0/1/2, F2/3/4 with 91.4% accuracy for FibroMeter, avoiding biopsy in all patients.
Conclusions FibroMeter NAFLD had high performance and provided reliable
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